Normal tumor marker levels for breast cancer depend on which marker is being measured, but the most commonly tested ones have well-defined upper limits: CA 15-3 should be below 30 kU/L, CA 27.29 should be below 38 U/mL, and CEA should be below 2.5 ng/mL. These numbers represent the cutoffs used by most labs, though slight variations exist between testing facilities and kits.
Understanding what these numbers mean, and what they don’t, is more useful than memorizing the thresholds alone. Tumor markers for breast cancer are imperfect tools. They can be normal even when cancer is present, and elevated even when it isn’t.
CA 15-3: The Most Widely Used Marker
CA 15-3 is the tumor marker most frequently ordered in the context of breast cancer. The standard upper limit of normal is 30 kU/L. Levels above 40 kU/L carry roughly an 83% probability of advanced disease, making that a particularly concerning threshold.
The catch is that CA 15-3 is not very sensitive in early-stage breast cancer. Many people with stage I or II disease have completely normal levels. This is why CA 15-3 is not used for screening or early detection. Its main role is monitoring women who have already been diagnosed with metastatic breast cancer, where rising or falling levels can help track whether treatment is working.
A number of non-cancerous conditions can push CA 15-3 above the normal range. These include liver cirrhosis, chronic hepatitis, tuberculosis, sarcoidosis, lupus, endometriosis, pelvic inflammatory disease, interstitial lung disease, and even pregnancy or lactation. The key difference is that in benign conditions, levels tend to stay relatively stable over time rather than climbing steadily upward.
CA 27.29: A Similar but Distinct Test
CA 27.29 measures a protein closely related to what CA 15-3 detects, and the two tests are often used interchangeably. The normal reference range for CA 27.29 is below 38 U/mL. Your doctor will typically order one or the other, not both, since they provide overlapping information.
Like CA 15-3, CA 27.29 can be elevated in several benign situations: first trimester pregnancy, endometriosis, ovarian cysts, benign breast disease, kidney disease, and liver disease. One important note is that results from different labs or different testing kits cannot be directly compared. If you’re tracking your levels over time, consistency in where and how the test is run matters.
CEA: A Less Specific Marker
Carcinoembryonic antigen, or CEA, is not specific to breast cancer. It can be elevated in colorectal, lung, pancreatic, and other cancers, as well as in several non-cancerous conditions. The normal range is 0 to 2.5 ng/mL for non-smokers. If you smoke, levels up to 5 ng/mL are still considered within the normal range because tobacco use alone can raise CEA.
CEA is sometimes ordered alongside CA 15-3 or CA 27.29 to give a broader picture during monitoring of advanced breast cancer. On its own, it’s not reliable enough to make treatment decisions for breast cancer specifically.
Circulating Tumor Cells
Circulating tumor cells (CTCs) are cancer cells that have broken away from a tumor and entered the bloodstream. Rather than measuring a protein level, this test counts actual cells in a blood sample. The clinically significant threshold is 5 or more CTCs per 7.5 mL of blood. In a large study of women starting chemotherapy for metastatic breast cancer, 44% had counts at or above this level, and those women had significantly shorter survival times regardless of their breast cancer subtype.
Despite the prognostic value of CTC counts, the American Society of Clinical Oncology (ASCO) does not currently recommend routine use of CTCs to monitor treatment response. The evidence is not yet strong enough to change treatment based on CTC numbers alone. The same applies to circulating tumor DNA (ctDNA), another blood-based approach that remains under investigation.
Why Normal Markers Don’t Rule Out Cancer
The most important thing to understand about breast cancer tumor markers is what they cannot do. They cannot reliably detect early-stage breast cancer. A person can have a growing tumor and still show perfectly normal CA 15-3, CA 27.29, and CEA levels. No major medical organization recommends using these blood tests to screen for breast cancer in the general population or to diagnose it in someone with a suspicious lump or mammogram finding.
Tumor markers are most useful in one specific scenario: tracking disease activity in someone already diagnosed with metastatic (stage IV) breast cancer. In that setting, a rising trend over several measurements is more meaningful than any single number. A one-time result slightly above the cutoff is often less informative than the direction the numbers are heading.
What an Elevated Result Actually Means
If your tumor marker comes back above the normal range, it does not automatically mean cancer is present or progressing. Your doctor will look at the result alongside imaging, symptoms, and your medical history. A single elevated reading might prompt a repeat test in a few weeks to see if the level is climbing, stable, or dropping back down.
Context matters enormously. Someone with known liver disease or an autoimmune condition like lupus may have chronically elevated CA 15-3 that has nothing to do with breast cancer. Pregnancy, particularly in the first trimester, can also raise both CA 15-3 and CA 27.29. The pattern over time, not a single snapshot, is what carries clinical weight.
If you’re being monitored after a breast cancer diagnosis, your care team will typically establish a personal baseline and watch for meaningful changes from that number rather than relying strictly on the general population cutoffs listed above. A level of 25 kU/L that was previously 12 kU/L tells a different story than a level that has sat at 25 for years.